Our previous reports demonstrate that PRL3 antibody therapy can inhibit PRL3+ tumors in multiple animal models using cancer cell lines derived from different origins, including ovarian, colorectal, melanoma, lung, AML, and gastric tissues (Supplementary Table 1). The gene discussed is PTP4A3; the disease is melanoma.